Sun Pharma to Acquire Checkpoint Therapeutics for $355 Million, Bolstering Onco-Dermatology Portfolio

2 min read   |   Updated on 10 Mar 2025, 07:50 AM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Sun Pharmaceutical Industries Ltd is set to acquire Nasdaq-listed Checkpoint Therapeutics, Inc. for up to $355 million. The deal includes an upfront payment of $4.10 per share and a potential additional $0.70 per share contingent on European regulatory approval for Cosibelimab. This acquisition will strengthen Sun Pharma's global specialty product portfolio, particularly in onco-dermatology. The key asset is UNLOXCYT™, an FDA-approved treatment for advanced cutaneous squamous cell carcinoma (cSCC). The deal is expected to close in the second quarter of 2025, subject to regulatory and stockholder approvals.

3118832

*this image is generated using AI for illustrative purposes only.

Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA, BSE: 524715), India's largest pharmaceutical company, has announced a strategic move to acquire Nasdaq-listed Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) for up to $355 million. This acquisition is set to strengthen Sun Pharma's global specialty product portfolio, particularly in the onco-dermatology segment.

Deal Structure and Valuation

The transaction involves:

  • An upfront cash payment of $4.10 per share of Checkpoint's common stock
  • A premium of approximately 66% to Checkpoint's closing share price on March 7, 2025
  • A non-transferable contingent value right (CVR) of up to an additional $0.70 per share, subject to regulatory approval for Cosibelimab in Europe

Strategic Rationale

Sun Pharma's Chairman & Managing Director, Dilip Shanghvi, emphasized the strategic importance of this acquisition:

"Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma's global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy."

Key Asset: UNLOXCYT

The centerpiece of this acquisition is UNLOXCYT™ (cosibelimab-ipdl), Checkpoint's FDA-approved treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. This addition significantly enhances Sun Pharma's position in the growing field of immuno-oncology.

Market Opportunity

Cutaneous squamous cell carcinoma (cSCC) represents a substantial market opportunity:

  • Second most common type of skin cancer in the United States
  • Estimated annual incidence of approximately 1.8 million cases in the U.S.
  • About 40,000 cases becoming advanced each year

Financial Aspects

For the nine-month period ending September 2024, Checkpoint reported:

Metric Amount (in millions)
Revenues $0.04
Net Loss $27.3
R&D Expenses $19.3

Closing Conditions and Timeline

  • Expected closing: Second calendar quarter of 2025
  • Subject to customary closing conditions, including regulatory approvals and Checkpoint stockholder approval
  • Fortress Biotech, Inc., Checkpoint's controlling stockholder, has agreed to vote in favor of the transaction

Industry Impact

This acquisition underscores:

  • Ongoing consolidation in the pharmaceutical industry, particularly in specialty and oncology segments
  • Sun Pharma's commitment to expanding its presence in the U.S. market
  • Strengthening of Sun Pharma's specialty medicine portfolio

Conclusion

The acquisition of Checkpoint Therapeutics represents a significant step for Sun Pharma in enhancing its global specialty product offerings, particularly in the high-growth area of onco-dermatology. With UNLOXCYT now in its portfolio, Sun Pharma is well-positioned to address the unmet needs of patients with advanced cSCC, leveraging its global presence to improve patient access to this innovative treatment.

As the pharmaceutical landscape continues to evolve, strategic acquisitions like this one demonstrate how companies are adapting to meet the growing demand for specialized and targeted therapies in oncology and dermatology.

Historical Stock Returns for Sun Pharmaceutical

1 Day5 Days1 Month6 Months1 Year5 Years
+3.45%+3.79%+2.77%-7.31%+15.50%+283.18%
Explore Other Articles
Havells India Sets Date for Q4 and FY25 Results, Dividend Announcement1 hour ago
Reliance Industries to Announce Q4 Results, Consider Dividend and Fundraising on April 252 hours ago
BHEL Reports 19% Revenue Surge and Record Order Inflows in FY 2024-252 hours ago
YES Bank Reports 63.3% Surge in Q4 Profit, Asset Quality Improves2 hours ago
Asian Energy Services Expands Global Footprint with $9.25 Million Acquisition of Kuiper Group22 hours ago
IRIS Business Services Secures Role in Qatar Central Bank's Regulatory Tech Project22 hours ago
1,751.50
+58.40
(+3.45%)